March 26, 2021

WATCH: Santhera Pharmaceuticals Duchenne Drug Development Update (Webinar Recording)

Santhera Pharmaceuticals joined Parent Project Muscular Dystrophy (PPMD) for a webinar on March 24, 2021 to provide an update to the community about the investigational therapy vamorolone, the use of steroids to treat Duchenne muscular…

Learn More

October 6, 2020

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne

Today, we are disappointed to learn that Santhera announced its decision to discontinue development of its Phase 3 SIDEROS study with Puldysa® (idebenone) in Duchenne. Santhera will stop the SIDEROS trial (including extension) and participants…

Learn More

May 20, 2020

Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne

Santhera announced today that their SIDEROS study is fully enrolled, with 254 participants ages 10-34 years old. PPMD is excited to learn that this trial is enrolled, allowing the study to continue and enabling Santhera…

Learn More

April 1, 2020

Santhera Shares Community Update on SIDEROS Trial & COVID-19

Santhera Pharmaceuticals has shared an update with the community regarding the SIDEROS clinical trial and their activities during the COVID-19 epidemic. Read the update from Santhera Dear Duchenne community, Much has changed in the world…

Learn More

January 21, 2020

Santhera Shares Winter 2020 Community Update

Santhera Pharmaceuticals shared a letter with the community, emphasizing that their main focus in the U.S. right now is to bring the SIDEROS clinical trial to full enrollment. Learn more about this clinical trial, including…

Learn More

September 25, 2019

Santhera Shares Fall 2019 Community Update

Santhera has shared a community update on the company’s Duchenne drug development programs and their partnership with ReveraGen. Click here to download.

Learn More

May 13, 2019

WATCH: Santhera Update to the Duchenne Community – Webinar Recording

On May 8, 2019, Santhera joined Parent Project Muscular Dystrophy for a webinar to provide the community with an update about respiratory health in Duchenne muscular dystrophy and the ongoing SIDEROS clinical trial. If you…

Learn More

February 25, 2019

Santhera’s SYROS Study Shows Long-term Efficacy with Idebenone in Slowing Respiratory Function Loss

Santhera Pharmaceuticals announced positive results from the SYROS study demonstrating that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne for up to 6 years in a real-world…

Learn More

May 18, 2018

Santhera Pharmaceuticals Launches Formal Expanded Access Program in the U.S.

PPMD is pleased to learn that Santhera Pharmaceuticals has launched a formal expanded access program in the U.S. for their investigational therapies, including idebenone. Learn more by visiting the Santhera website.

Learn More